Gene: CNTN4

152330
AXCAM|BIG-2
contactin 4
protein-coding
3p26.3-p26.2
Ensembl:ENSG00000144619 MIM:607280 Vega:OTTHUMG00000119031 UniprotKB:Q8IWV2
NG_012827.1
PubMed|SNP Mapped
6   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.255e-1 (AD)  1.523e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs17022006chr3:2897050 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)
rs7611373chr3:2875753 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs1479540chr3:2587793 (GRCh38.p7)A>Gnicotine dependenceSNV(Single Nucleotide Variation)
rs2728055chr3:2574606 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs11707897chr3:2572942 (GRCh38.p7)T>Cnicotine dependence|alcohol dependenceSNV(Single Nucleotide Variation)
rs6792956chr3:2371163 (GRCh38.p7)T>Cnicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OLFM30.953
FRMPD40.951
GABRA10.95
HCN10.948
ADAM220.948
ATRNL10.947
SLC4A100.947
SCN2A0.946
GABRB20.946
PLCB10.946

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HEY2-0.58
CSAG1-0.569
RAB13-0.562
ROM1-0.546
COPZ2-0.539
MYL3-0.539
EMP3-0.536
CHST14-0.535
RNF135-0.535
CMTM3-0.531

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of CNTN4 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN4 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of CNTN4 mRNA26690555
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of CNTN4 gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of CNTN4 gene28458013
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
D001564Benzo(a)pyreneBenzo(a)pyrene metabolite results in decreased expression of CNTN4 mRNA26314263
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of CNTN4 mRNA25181051
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
D002104CadmiumCadmium results in increased expression of CNTN4 mRNA21120746
D003471CuprizoneCuprizone results in decreased expression of CNTN4 mRNA26577399
D0198131,2-Dimethylhydrazine"[APC protein affects the susceptibility to 1,2-Dimethylhydrazine] which results in decreased expression of CNTN4 mRNA"27840820
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
C025340manganese chloridemanganese chloride results in decreased expression of CNTN4 mRNA15295902
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of CNTN4 mRNA26272509|2800136
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN4 mRNA"27188386
D009151Mustard GasMustard Gas results in increased expression of CNTN4 mRNA15674844
D009532NickelNickel results in decreased expression of CNTN4 mRNA24768652|2558310
C025589ochratoxin Aochratoxin A metabolite results in decreased expression of CNTN4 mRNA26314263
C025589ochratoxin Aochratoxin A results in decreased expression of CNTN4 mRNA26314263
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of CNTN4 mRNA25607892
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of CNTN4 mRNA"25510870
D011441PropylthiouracilPropylthiouracil results in decreased expression of CNTN4 mRNA24780913
D014212TretinoinTretinoin results in decreased expression of CNTN4 mRNA23724009
D014212TretinoinTretinoin results in increased expression of CNTN4 mRNA21934132
D014635Valproic AcidValproic Acid results in decreased methylation of CNTN4 gene29154799
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of CNTN4 gene25560391
D019287Zinc SulfateZinc Sulfate results in decreased expression of CNTN4 mRNA27215404

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO ID GO Term Qualifier Evidence PubMed
GO:0007158neuron cell-cell adhesion-TAS14571131  
GO:0007399nervous system development-IMP15106122  
GO:0007409axonogenesis-TAS14571131  
GO:0007411axon guidance-TAS15106122  
GO:0007413axonal fasciculation-TAS15106122  
GO:0007420brain development-ISS-  
GO:0031175neuron projection development-ISS-  
GO:0045665negative regulation of neuron differentiation-IMP14571131  
GO:0048167regulation of synaptic plasticity-TAS15106122  
GO ID GO Term Qualifier Evidence PubMed
GO:0005576extracellular region-TAS-  
GO:0005886plasma membrane-NAS15106122  
GO:0005886plasma membrane-TAS-  
GO:0030424axon-NAS14571131  
GO:0031225anchored component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-163125Post-translational modification: synthesis of GPI-anchored proteinsTAS
R-HSA-392499Metabolism of proteinsTAS
R-HSA-597592Post-translational protein modificationTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28044437Body mass index change in gastrointestinal cancer and chronic obstructive pulmonary disease is associated with Dedicator of Cytokinesis 1. (2017 Jun)McDonald MNJ Cachexia Sarcopenia Muscle
25889363Personal exposure to PM2.5, genetic variants and DNA damage: a multi-center population-based study in Chinese. (2015 Jun 15)Chu MToxicol Lett